Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2015 Dicembre;40(4) > Minerva Endocrinologica 2015 Dicembre;40(4):321-9

ULTIMO FASCICOLOMINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

REVIEWS  


Minerva Endocrinologica 2015 Dicembre;40(4):321-9

lingua: Inglese

Endocrine manifestations of chronic HCV infection

Caviglia G. P. 1, Rosso C. 1, Fagoonee S. 2, Cisarò F. 3, Andrealli A. 4, Smedile A. 1, 3, Pellicano R. 3

1 Department of Medical Sciences, University of Turin, Turin, Italy;
2 Institute for Biostructures and Bioimages (CNR), c/o Molecular Biotechnology Center, University of Turin, Turin, Italy;
3 Department of Gastroenterology and Hepatology, Molinette Hospital Turin, Italy;
4 Unit of Gastroenterology and Digestive Endoscopy, Valduce Hospital, Como, Italy


PDF  ESTRATTI


Chronic hepatitis C virus (HCV) infection has been associated with a great number of extra-hepatic manifestations (EHMs), including several endocrine disorders. Currently available epidemiological, clinical and experimental data do not show a link between HCV and all EHMs. Thyroid disorders (TD) and type 2 diabetes, for example, are the most frequent endocrine alterations in patients with chronic HCV infection, but there are only weak evidences that HCV could be involved in hypothalamic-pituitary axis perturbation, bone metabolism alteration and sexual dysfunctions induction. Thus, this issue needs further investigation. Prospective studies have also shown that interferon (IFN)-based therapy for chronic HCV infection can induce or worsen EHMs. In particular, IFN has been associated with development of autoimmunity and/or TD in up to 40% of chronic HCV infected patients. Hence, a careful monitoring of thyroid function should be performed in such patients. The recent approval of direct-acting antiviral agents in IFN-free regimens for chronic hepatitis C treatment will dramatically reduce not only liver-related mortality but also morbidity due to EHMs.

inizio pagina